Form4insider filings, from the source

SEC Form 4 · accession 0001920738-26-000004

4D Molecular Therapeutics, Inc. · FDMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Scott Bizily
Officer — Chief Legal Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:07 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001650648

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJun 30, 2026M814$4.14A9,431D
Common StockJun 30, 2026M5,752$6.49A15,183D
Common StockJun 30, 2026S6,566$14.00D8,617D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2$4.14Jun 30, 2026M814D—Mar 5, 2035Common Stock81462,971D
Stock Option (Right to Buy)F3$6.49Jun 30, 2026M5,752D—Jun 17, 2032Common Stock5,7523,543D

Explanation of responses